Concord Drugs Limited
Bombay Stock ExchangeTotal Valuation
Concord Drugs Limited carries a market capitalization of 892.97M, placing it among publicly traded companies globally. Its enterprise value stands at 920.78M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 892.97M |
| Enterprise Value | 920.78M |
Valuation Ratios
Concord Drugs Limited trades at a trailing price-to-earnings ratio of 162.71.
| PE Ratio | 162.71 |
| PS Ratio | 1.80 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Concord Drugs Limited trades at an EV/EBITDA multiple of 33.24 and an EV/FCF ratio of 67.37. The EV/Sales ratio of 1.80 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 33.24 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.80 |
| EV / EBITDA | 33.24 |
| EV / EBIT | 33.24 |
| EV / FCF | 67.37 |
Financial Position
Concord Drugs Limited maintains a current ratio of 3.10, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 106.07, indicating elevated leverage, while an interest coverage ratio of 1.46 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.10 |
| Quick Ratio | 0.02 |
| Debt / Equity | 106.07 |
| Debt / EBITDA | N/A |
| Interest Coverage | 1.46 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -3.73 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Concord Drugs Limited has paid 2.18M in income taxes, reflecting an effective tax rate of 27.80.
| Income Tax | 2.18M |
| Effective Tax Rate | 27.80 |
Stock Price Statistics
Concord Drugs Limited's stock has gained approximately 156.16438% over the past 52 weeks. The 50-day moving average sits at 79.25, while the 200-day moving average is 75.29.
| Beta (5Y) | N/A |
| 52-Week Price Change | 156.16438% |
| 50-Day Moving Average | 79.25 |
| 200-Day Moving Average | 75.29 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Concord Drugs Limited generated 512.41M in revenue and converted that into 5.66M in net income, yielding earnings per share of 0.51. EBITDA reached 27.70M, while operating income came in at 27.70M.
| Revenue | 512.41M |
| Gross Profit | 98.06M |
| Operating Income | 27.70M |
| Pretax Income | 7.84M |
| Net Income | 5.66M |
| EBITDA | 27.70M |
| EBIT | 27.70M |
| Earnings Per Share (EPS) | 0.51 |
Margins
Concord Drugs Limited operates with a gross margin of 19.14, reflecting its pricing power and cost economics. The operating margin of 5.41 and net profit margin of 1.10 provide insight into operational efficiency.
| Gross Margin | 19.14 |
| Operating Margin | 5.41 |
| Pretax Margin | 1.53 |
| Profit Margin | 1.10 |
| EBITDA Margin | 5.41 |
Scores
Concord Drugs Limited posts an Altman Z-Score of 3.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.71 |